SOURCE: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

January 07, 2015 08:05 ET

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

Biotech Showcase 2015 Presentation on Wednesday, January 14, 2015; Noble Financial Capital Markets' Eleventh Annual Equity Conference Presentation on Tuesday, January 20, 2015

NORWOOD, MA--(Marketwired - Jan 7, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab, for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at two upcoming investor conferences in January, 2015.

Event: Biotech Showcase 2015
Date: Wednesday, January 14, 2015
Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
Location: Parc 55 Wyndham Union Square, San Francisco, CA

Event: Noble Financial Capital Markets' 11th Annual Investor Conference
Date: Tuesday, January 20, 2015
Time: 9:00 a.m. Eastern Time
Location: Club Med, Sandpiper Bay, FL

Dr. Cohen will provide a corporate overview with a specific focus on the clinical development plans for the Company's lead product candidate Resunab, a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity, under development for cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (scleroderma).

Live webcasts of both presentations will be available on the Company's website (www.CorbusPharma.com) by accessing the IR Calendar in the News and Events section of the Investor Relations page. The webcast replays will be available approximately two hours after each presentation ends and will be accessible for one month.

About Resunab™
Resunab™ is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."

About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate Resunab is a novel oral anti-inflammatory drug scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse scleroderma in 2015. For more information, please visit www.CorbusPharma.com.

Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission or otherwise. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," "will" and similar expressions and the negatives of those terms. These statements involve known and unknown risks, uncertainties, and other factors, including the statements set forth under "Expected Near-Term Milestones," which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact Information